Literature DB >> 24127047

[Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs].

L Klimek1, J Willers, P Schendzielorz, T M Kündig, G Senti.   

Abstract

BACKGROUND: Allergen-specific immunotherapy is generally accepted as the only causal therapy for allergic rhinitis. Up to now there has been a dogma in immunotherapy for inhalation allergies that at least allergen components are necessary for effective therapy. This dogma could, however, be swayed by current results of effective immunotherapy without allergens. Virus-like particles (VLP) represent a novel and interesting aspect for immunotherapy for inhalation allergies. AIM: Initial experiences with successful immunotherapy without allergens are available. This article describes the currently available clinical experiences with bacteriophage VLPs filled with oligonucleotides which contain CpG motifs with tumor antigens on the surface for the treatment of allergic rhinitis.
RESULTS: Vaccination with VLPs was found to be well tolerated, immunogenic and effective for prophylactic treatment of various infections. Bacteriophage VLPs filled with CpG motifs with tumor antigens on the surface led clinically to an induction of specific T-cells in tumor patients and were successfully implemented as adjuvants during prophylactic vaccinations.
CONCLUSION: The VLP technique in combination with the use of CpG motifs could contribute to the causal treatment of complex diseases, such as malignancies, autoimmune diseases and allergies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24127047     DOI: 10.1007/s00106-013-2761-9

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  27 in total

1.  [Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis].

Authors:  L Klimek; P Högger; O Pfaar
Journal:  HNO       Date:  2012-07       Impact factor: 1.284

Review 2.  Mechanisms of allergen specific immunotherapy--T-cell tolerance and more.

Authors:  M Jutel; M Akdis; K Blaser; C A Akdis
Journal:  Allergy       Date:  2006-07       Impact factor: 13.146

Review 3.  The coming of age of virus-like particle vaccines.

Authors:  Gary T Jennings; Martin F Bachmann
Journal:  Biol Chem       Date:  2008-05       Impact factor: 3.915

Review 4.  T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases.

Authors:  Mübeccel Akdis; Kurt Blaser; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2005-10-10       Impact factor: 10.793

5.  The influence of antigen organization on B cell responsiveness.

Authors:  M F Bachmann; U H Rohrer; T M Kündig; K Bürki; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1993-11-26       Impact factor: 47.728

Review 6.  CpG DNA as a vaccine adjuvant.

Authors:  Christian Bode; Gan Zhao; Folkert Steinhagen; Takeshi Kinjo; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

7.  [Management of anaphylaxis : part 2: treatment and emergency equipment].

Authors:  L Klimek; U Goebel; A Glowania
Journal:  HNO       Date:  2012-12       Impact factor: 1.284

8.  Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.

Authors:  G Senti; P Johansen; S Haug; C Bull; C Gottschaller; P Müller; T Pfister; P Maurer; M F Bachmann; N Graf; T M Kündig
Journal:  Clin Exp Allergy       Date:  2009-02-16       Impact factor: 5.018

Review 9.  Eat dirt: CpG DNA and immunomodulation of asthma.

Authors:  Joel N Kline
Journal:  Proc Am Thorac Soc       Date:  2007-07

10.  Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial.

Authors:  Gabriela Senti; Bettina M Prinz Vavricka; Iris Erdmann; Mella I Diaz; Richard Markus; Stephen J McCormack; John J Simard; Brunello Wüthrich; Reto Crameri; Nicole Graf; Pål Johansen; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-10       Impact factor: 11.205

View more
  2 in total

Review 1.  [Molecular component-resolved allergy diagnostics in ENT].

Authors:  L Klimek; S Becker
Journal:  HNO       Date:  2017-10       Impact factor: 1.284

Review 2.  Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform.

Authors:  Oliver Pérez; Belkis Romeu; Osmir Cabrera; Elizabeth González; Alexander Batista-Duharte; Alexis Labrada; Rocmira Pérez; Laura M Reyes; Wendy Ramírez; Sergio Sifontes; Nelson Fernández; Miriam Lastre
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.